Business of regenerative medicine: comparability and the regulatory revolution

In the second part of RegMedNet’s expert panel on the business of regenerative medicine, learn more about how comparability and regulation can affect a regenerative medicine’s path to commercialization. Plus, the panelists share their experiences of regulatory systems around the world.

Chaired by Michael May, CCRM, this panel discussion focuses on the key business challenges within regenerative medicine. Joining Michael were four leading voices in regenerative medicine and cell therapy, from research to manufacture: Robert Preti (Hitachi Chemical Advanced Therapeutics Solutions, LLC), Robert Jones (Fisher Bioservices), Carolyn Yeago (Georgia Institute of Technology) and Qasim Rafiq (UCL).

The panel discussion took place in May 2018.

Learn more on RegMedNet’s website.

MaRS Centre, West Tower
661 University Avenue, Suite 1002
Toronto, Ontario M5G 1M1 Canada
t: 416-978-3751
f: 416-978-1368

We wish to acknowledge this land on which CCRM operates. For thousands of years, it has been the traditional land of the Huron-Wendat, the Seneca, and the Mississaugas of the Credit. Today, this meeting place is still the home to many Indigenous people from across Turtle Island and we are grateful to have the opportunity to work on this land.